Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

August 12, 2016

Study Completion Date

October 26, 2016

Conditions
Hepatitis C, Chronic
Interventions
DRUG

TG-2349

TG-2349 (Furaprevir) is available as a Swedish orange capsule (size 0) for oral administration. Each capsule contains an equivalent of 100 mg of TG-2349 spray dried solid (SDD) and the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, and colloidal silicon oxide.

DRUG

Ribavirin

RBV (Ribavirin or COPEGUS®) is available as a light pink to pink colored, flat, oval-shaped, film-coated tablet for oral administration. Each tablet contains 200 mg of ribavirin and the following inactive ingredients: pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, cornstarch, and magnesium stearate. The coating of the tablet contains Chromatone-P® or Opadry® Pink (made by using hydroxypropyl methyl cellulose, talc, titanium dioxide, synthetic yellow iron oxide, and synthetic red iron oxide), ethyl cellulose (ECD-30), and triacetin.

DRUG

Interferon Alfa-2a

"IFN (Interferon, Peg-interferon alpha-2a or PEGASYS®) is available as a sterile, preservative-free, colorless to light yellow injectable solution administered subcutaneously.~Each prefilled syringe of 180 μg/0.5 mL IFN (expressed as the amount of interferon alfa-2a) also contains acetic acid (0.0231 mg), benzyl alcohol (5 mg), polysorbate 80 (0.025 mg), sodium acetate trihydrate (1.3085 mg), and sodium chloride (4 mg) at pH 6 ± 0.5."

Trial Locations (1)

Unknown

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

All Listed Sponsors
lead

TaiGen Biotechnology Co., Ltd.

INDUSTRY

NCT02340962 - Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection | Biotech Hunter | Biotech Hunter